uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says
uniQure seeks accelerated FDA approval for its Huntington's gene therapy, AMT-130. William Blair resumes coverage with a $73 fair price.
uniQure asked the FDA to review their new medicine for Huntington's disease faster than usual. If the FDA says yes, it could be a big moment for the company—so watch to see if the agency approves it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.